

## New Hampshire AIDS Drug Assistance Program Prior Authorization Drug Approval Form

Zurzuvae™ (zuranolone)

DATE OF MEDICATION REQUEST: / /

SECTION I: PATIENT INFORMATION AND MEDICATION REQUESTED														
LAST NAME:	FIRST NAME:													
MEDICAID ID NUMBER:	DATE OF BIRTH:													
GENDER: Male Female														
Orug Name:	Strength:													
Danius Divertions	Loughth of Thomas													
Dosing Directions:	Length of Therapy:													
<del>-</del>														
SECTION II: PRESCRIBER INFORMATION														
AST NAME:	FIRST NAME:													
SPECIALTY:	NPI NUMBER:													
PHONE NUMBER:	FAX NUMBER:													
SECTION III: CLINICAL HISTORY:														
1. Is the prescriber a psychiatrist or obstetrician/gyneco	ologist or has one been consulted? Yes No													
Does the patient have a diagnosis of severe postpartum depression determined by a Yes No standardized screening tool?														
3. Date of the onset of symptoms of postpartum depression:														
1. Date of delivery:														
. Has the patient received counseling concerning the potential risk of fetal harm?														
. Has the patient ceased lactating or will the patient refrain from providing breast milk to the Yes No infant from the first dose until 7 days after the last dose?														
Form continued on next page.)														





## **New Hampshire AIDS Drug Assistance Program** Prior Authorization Drug Approval Form Zurzuvae™ (zuranolone)

SECTION III: CLINICAL HISTORY (Continued)  7. Has the patient been counseled to avoid potentially hazardous activities requiring mental alertness for at least 12 hours after each dose?  8. Has the patient been counseled to take the medication with 400–1,000 calories of food containing 25–50% fat?  9. Is the patient taking another oral antidepressant and has been on a stable dose for 30 or more days?  10. Have drug interactions been considered with dosage adjustments when needed? Yes fif yes, indicate the dose adjustment:  11. Does the patient have any baseline renal or hepatic dysfunction? Yes fif yes, indicate the dose adjustment:  12. Does the patient have eGFR less than 15 mL/min/1.73 m² or require dialysis? Yes diditional space is needed, please use a separate sheet.	<u></u>	PATIENT LAST NAME:													FIRC.	ΓΝΔΓ	ИF·						
7. Has the patient been counseled to avoid potentially hazardous activities requiring mental alertness for at least 12 hours after each dose?  8. Has the patient been counseled to take the medication with 400–1,000 calories of food containing 25–50% fat?  9. Is the patient taking another oral antidepressant and has been on a stable dose for 30 or more days?  10. Have drug interactions been considered with dosage adjustments when needed?  11. Does the patient have any baseline renal or hepatic dysfunction?  12. If yes, indicate the dose adjustment:  12. Does the patient have eGFR less than 15 ml/min/1.73 m² or require dialysis?  13. Provide any additional information that would help in the decision-making process.  14 additional space is needed, please use a separate sheet.		T			/IL.							]					VIL.				$\overline{1}$		
7. Has the patient been counseled to avoid potentially hazardous activities requiring mental alertness for at least 12 hours after each dose?  8. Has the patient been counseled to take the medication with 400–1,000 calories of food containing 25–50% fat?  9. Is the patient taking another oral antidepressant and has been on a stable dose for 30 or more days?  10. Have drug interactions been considered with dosage adjustments when needed?  11. Does the patient have any baseline renal or hepatic dysfunction?  12. If yes, indicate the dose adjustment:  12. Does the patient have eGFR less than 15 ml/min/1.73 m² or require dialysis?  13. Provide any additional information that would help in the decision-making process.  14 additional space is needed, please use a separate sheet.																							
alertness for at least 12 hours after each dose?  8. Has the patient been counseled to take the medication with 400–1,000 calories of food containing 25–50% fat?  9. Is the patient taking another oral antidepressant and has been on a stable dose for 30 or more days?  10. Have drug interactions been considered with dosage adjustments when needed? Yes fixes, indicate the dose adjustment:  11. Does the patient have any baseline renal or hepatic dysfunction? Yes fixes, indicate the dose adjustment:  12. Does the patient have eGFR less than 15 mL/min/1.73 m² or require dialysis? Yes fixes additional information that would help in the decision-making process. If additional space is needed, please use a separate sheet.	SE	CTION	I III: C	LINIC	AL H	ISTO	RY <i>(C</i>	Conti	nued)														
containing 25–50% fat?  9. Is the patient taking another oral antidepressant and has been on a stable dose for 30 or more days?  10. Have drug interactions been considered with dosage adjustments when needed? Yes 1. Does the patient have any baseline renal or hepatic dysfunction? Yes 1. If yes, indicate the dose adjustment: 1. Does the patient have eGFR less than 15 mL/min/1.73 m² or require dialysis? Yes 1. Provide any additional information that would help in the decision-making process. If additional space is needed, please use a separate sheet.	7.	·																Yes	☐ No				
days?  10. Have drug interactions been considered with dosage adjustments when needed? Yes   11. Does the patient have any baseline renal or hepatic dysfunction? Yes   12. Does the patient have eGFR less than 15 mL/min/1.73 m² or require dialysis? Yes   13. Provide any additional information that would help in the decision-making process. If additional space is needed, please use a separate sheet.	8.																	Yes	☐ No				
11. Does the patient have any baseline renal or hepatic dysfunction?    If yes, indicate the dose adjustment:    12. Does the patient have eGFR less than 15 mL/min/1.73 m² or require dialysis?	9.																·e	Yes	☐ No				
If yes, indicate the dose adjustment:	10.	10. Have drug interactions been considered with dosage adjustments when needed?															Yes	☐ No					
12. Does the patient have eGFR less than 15 mL/min/1.73 m² or require dialysis?  13. Provide any additional information that would help in the decision-making process.  If additional space is needed, please use a separate sheet.  I certify that the information provided is accurate and complete to the best of my knowledge and I understand	11.	11. Does the patient have any baseline renal or hepatic dysfunction?												Yes	☐ No								
13. Provide any additional information that would help in the decision-making process. If additional space is needed, please use a separate sheet. I certify that the information provided is accurate and complete to the best of my knowledge and I understand		If yes	s, indi	icate <sup>-</sup>	the d	lose a	adjus	tmen	it:									_					
If additional space is needed, please use a separate sheet.  I certify that the information provided is accurate and complete to the best of my knowledge and I understand	12.	Does	the <sub>l</sub>	patier	nt ha	ve e0	SFR le	ess th	an 15	mL/n	nin/1.	73	m² o	r req	uire	dialys	is?					Yes	☐ No
	13.			•							-			ecisi	on-m	aking	g pro	cess.					
PRESCRIBER'S SIGNATURE: DATE:	tha	t any	falsit	ficatio	on, oi	missi	-						-				me t	to civ	il or	_			nd

Phone: 1-800-424-7901 Fax: 1-800-424-7984

